S&P: Kyphon unchanged

Standard & Poor's said its rating and outlook on Kyphon Inc. (B+/positive) would not be affected by the company's intention to purchase all of the spine-related product assets and associated intellectual property rights of Disc-O-Tech Medical Technologies Ltd. for $240 million, including contingent payments.

The agency said that this acquisition was already factored into its current rating and outlook.

The agency added it anticipates that Kyphon will now focus on integrating its recent acquisitions and improving its financial risk profile.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.